Lu AF35700 clinical trials
How each study uses Lu AF35700 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Name
- Lu AF35700
- 10
Studies by the year they started
13 studies that test it; most in 2017 (5)
| Year | Studies |
|---|---|
| 2013 | 1 |
| 2014 | 2 |
| 2016 | 3 |
| 2017 | 5 |
| 2018 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 13 · Other 0
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses Lu AF35700 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 13
- Flexible-dose, Long-term Safety Study of Lu AF35700 in Adult Patients With SchizophreniaCompletedPhase 3H. Lundbeck A/SNCT02892422Written as Lu AF35700
- Positron Emission Tomography (PET) Study Investigating Dopamine and Serotonin Receptor Occupancy After Multiple Oral Dosing of Lu AF35700CompletedPhase 1H. Lundbeck A/SNCT02333487Written as Lu AF35700
- Efficacy of Lu AF35700 in Patients With Early-in-disease or Late-in-disease Treatment-resistant SchizophreniaTerminatedPhase 3H. Lundbeck A/SNCT03230864Written as Lu AF35700
- Effect of Lu AF35700 in Patients With Treatment-resistant SchizophreniaCompletedPhase 3H. Lundbeck A/SNCT02717195Written as Lu AF35700
- Study With Lu AF35700 in Healthy Men and Women in Fasting and Fed StateCompletedPhase 1H. Lundbeck A/SNCT03670082Written as Lu AF35700
- Study Evaluating the Effect of Multiple Doses of Itraconazole on the Drug Lu AF35700 in Healthy Young Men and WomenCompletedPhase 1H. Lundbeck A/SNCT03103646Written as Lu AF35700
- Pharmacokinetics of Lu AF35700 in Subjects With Renal ImpairmentTerminatedPhase 1H. Lundbeck A/SNCT03241147Written as Lu AF35700
- Study Investigating the Effect of Lu AF35700 on Cardiac Repolarization in Men and Women With Schizophrenia and Schizoaffective DisorderCompletedPhase 1H. Lundbeck A/SNCT02901587Written as Lu AF35700 (10 mg/day)
- Bioequivalence Study of Lu AF35700CompletedPhase 1H. Lundbeck A/SNCT03394482Written as Lu AF35700 5 mg clinical formulation
- Study Investigating the Pharmacokinetic Properties of the Drug Lu AF35700 in Subjects With Liver Impairment and in Healthy SubjectsCompletedPhase 1H. Lundbeck A/SNCT03189615Written as Lu AF35700
- Effects of Repeated Doses of Lu AF35700 on Drug Metabolizing EnzymesCompletedPhase 1H. Lundbeck A/SNCT03195946Written as Lu AF35700
- Safety and Tolerability Study of Lu AF35700 After Repeated Dosing in Patients With SchizophreniaCompletedPhase 1H. Lundbeck A/SNCT02202226Written as Lu AF35700
- D2 Dopamine Receptor Occupancy After Oral Dosing of Lu AF35700 in Healthy Men Using [11C]-PHNO as Tracer CompoundCompletedPhase 1H. Lundbeck A/SNCT02093169Written as Part A: Lu AF35700